GSK$48.07
$48.12
Chart
Performance
Key Stats
AI GSK Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyGSK plc presents a mixed investment profile. Fundamentally sound with strong profitability and a solid balance sheet, but recent performance and valuation metrics warrant attention. Thematic tailwinds are present but not as pronounced as in other sectors. Technicals suggest a consolidation phase after recent gains.
Thematic
GSK operates in the healthcare and pharmaceutical sectors, benefiting from stable demand and demographic trends. Its focus on vaccines and specialty medicines provides some growth drivers, but it faces intense competition and regulatory hurdles.
Fundamental
GSK demonstrates strong profitability and a stable balance sheet with manageable debt. Revenue and net income have shown resilience, though growth rates can fluctuate based on drug approvals and market dynamics. Dividend yield is attractive.
Technical
The stock is trading near its 52-week high, indicating recent positive momentum. However, some oscillators suggest it may be approaching overbought territory, signaling a potential for a brief pause or minor retracement.
| Factor | Score |
|---|---|
| Healthcare Demand | 80 |
| Pharmaceutical Innovation | 75 |
| Vaccine Market Strength | 85 |
| Regulatory Environment | 60 |
| ESG Integration | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 65 |
| Growth | 60 |
| Balance Sheet Health | 70 |
| Cash Flow | 75 |
| Dividends | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Volume Confirmation | 65 |
| Support & Resistance | 75 |
| Short-Term Indicators | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Beat
The company has exceeded earnings per share (EPS) estimates for the last 7 reported quarters, demonstrating a consistent ability to outperform expectations.
Strong Free Cash Flow Generation
Free Cash Flow (FCF) has shown an upward trend, increasing from $4.42 billion in 2023 to $6.55 billion in 2024, indicating robust cash generation.
Bearish Points (7)
High P/S Ratio
The Price-to-Sales (P/S) ratio of 3.3 for TTM is relatively high compared to its 2024 projected P/S of 2.1, suggesting potential overvaluation based on current sales.
Declining Net Margin
Net margin has significantly decreased from 51.0% in 2022 to 8.2% in 2024, indicating potential pressure on profitability.
Calendar
May 2025
16
Ex-Dividend Date
July 2025
10
Next Dividend Date
July 2025
30
Next Earnings Date
H: $1.12
A: $1.11
L: $1.10
H: 8.29B
A: 7.82B
L: 7.65B
Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Seasonals
Price Target
41.34 USD
The 39 analysts offering 1 year price forecasts for GSK have a max estimate of 58.00 and a min estimate of 35.25.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct major competitor across multiple therapeutic areas including vaccines, oncology, and immunology, similar global pharmaceutical presence.
Weight: 95
Close direct competitor with strong overlapping therapeutic areas, particularly oncology, cardiovascular, renal, metabolism (CVRM), and respiratory.
Weight: 92
Major global pharmaceutical competitor with a diverse portfolio, including innovative medicines in oncology, immunology, and neuroscience, similar R&D focus.
Weight: 92
Global pharmaceutical leader with a strong R&D pipeline, especially in diabetes and obesity, making it a significant peer in the broader pharma landscape.